About Us Services Careers FAQ Contact Us 0
Home Pharmaceuticals Thyroid Cancer Drugs Market Size to Jump at US$4.3 billion by 2031
Thyroid Cancer Drugs Market

Thyroid Cancer Drugs Market Size, Share & Trends Analysis Report By Type (Papillary Thyroid Cancer, Follicular Thyroid Cancer, Hurthle Cell Cancer, Medullary Thyroid Cancer (MTC), Anaplastic Thyroid Cancer), By Treatment (Medication, Chemotherapy, Radioactive Iodine (Radioiodine) Therapy, Hormone Therapy), By Drug Type (Thyroid Desiccated, Sorafenib, Thyrotropin Alfa, Vandetanib, Doxorubicin, Cabozantinib, Lenvatini, Sodium Iodide I-131, Dabrafenib, Trametinib, Others), By Route of Administration (Oral, Injectable, Others), By End-Users (Hospitals, Homecare, Specialty Clinics, Others) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2023-2031

Report Code: SRPH55851DR
Author : Straits Research
Buy Now
File Formats

Table Of Content

  1. Executive Summary
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  2. ESG Trends
    1. Global Thyroid Cancer Drugs Market Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Papillary Thyroid Cancer
        1. By Value
      3. Follicular Thyroid Cancer
        1. By Value
      4. Hurthle Cell Cancer
        1. By Value
      5. Medullary Thyroid Cancer (MTC)
        1. By Value
      6. Anaplastic Thyroid Cancer
        1. By Value
    3. By Treatment
      1. Introduction
        1. Treatment By Value
      2. Medication
        1. By Value
      3. Chemotherapy
        1. By Value
      4. Radioactive Iodine (Radioiodine) Therapy
        1. By Value
      5. Hormone Therapy
        1. By Value
    4. By Drug Type
      1. Introduction
        1. Drug Type By Value
      2. Thyroid Desiccated
        1. By Value
      3. Sorafenib
        1. By Value
      4. Thyrotropin Alfa
        1. By Value
      5. Vandetanib
        1. By Value
      6. Doxorubicin
        1. By Value
      7. Cabozantinib
        1. By Value
      8. Lenvatini
        1. By Value
      9. Sodium Iodide I-131
        1. By Value
      10. Dabrafenib
        1. By Value
      11. Trametinib
        1. By Value
      12. Others
        1. By Value
    5. By Route of Administration
      1. Introduction
        1. Route of Administration By Value
      2. Oral
        1. By Value
      3. Injectable
        1. By Value
      4. Others
        1. By Value
    6. By End-Users
      1. Introduction
        1. End-Users By Value
      2. Hospitals
        1. By Value
      3. Homecare
        1. By Value
      4. Specialty Clinics
        1. By Value
      5. Others
        1. By Value
    1. Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Papillary Thyroid Cancer
        1. By Value
      3. Follicular Thyroid Cancer
        1. By Value
      4. Hurthle Cell Cancer
        1. By Value
      5. Medullary Thyroid Cancer (MTC)
        1. By Value
      6. Anaplastic Thyroid Cancer
        1. By Value
    3. By Treatment
      1. Introduction
        1. Treatment By Value
      2. Medication
        1. By Value
      3. Chemotherapy
        1. By Value
      4. Radioactive Iodine (Radioiodine) Therapy
        1. By Value
      5. Hormone Therapy
        1. By Value
    4. By Drug Type
      1. Introduction
        1. Drug Type By Value
      2. Thyroid Desiccated
        1. By Value
      3. Sorafenib
        1. By Value
      4. Thyrotropin Alfa
        1. By Value
      5. Vandetanib
        1. By Value
      6. Doxorubicin
        1. By Value
      7. Cabozantinib
        1. By Value
      8. Lenvatini
        1. By Value
      9. Sodium Iodide I-131
        1. By Value
      10. Dabrafenib
        1. By Value
      11. Trametinib
        1. By Value
      12. Others
        1. By Value
    5. By Route of Administration
      1. Introduction
        1. Route of Administration By Value
      2. Oral
        1. By Value
      3. Injectable
        1. By Value
      4. Others
        1. By Value
    6. By End-Users
      1. Introduction
        1. End-Users By Value
      2. Hospitals
        1. By Value
      3. Homecare
        1. By Value
      4. Specialty Clinics
        1. By Value
      5. Others
        1. By Value
    7. U.S.
      1. By Type
        1. Introduction
          1. Type By Value
        2. Papillary Thyroid Cancer
          1. By Value
        3. Follicular Thyroid Cancer
          1. By Value
        4. Hurthle Cell Cancer
          1. By Value
        5. Medullary Thyroid Cancer (MTC)
          1. By Value
        6. Anaplastic Thyroid Cancer
          1. By Value
      2. By Treatment
        1. Introduction
          1. Treatment By Value
        2. Medication
          1. By Value
        3. Chemotherapy
          1. By Value
        4. Radioactive Iodine (Radioiodine) Therapy
          1. By Value
        5. Hormone Therapy
          1. By Value
      3. By Drug Type
        1. Introduction
          1. Drug Type By Value
        2. Thyroid Desiccated
          1. By Value
        3. Sorafenib
          1. By Value
        4. Thyrotropin Alfa
          1. By Value
        5. Vandetanib
          1. By Value
        6. Doxorubicin
          1. By Value
        7. Cabozantinib
          1. By Value
        8. Lenvatini
          1. By Value
        9. Sodium Iodide I-131
          1. By Value
        10. Dabrafenib
          1. By Value
        11. Trametinib
          1. By Value
        12. Others
          1. By Value
      4. By Route of Administration
        1. Introduction
          1. Route of Administration By Value
        2. Oral
          1. By Value
        3. Injectable
          1. By Value
        4. Others
          1. By Value
      5. By End-Users
        1. Introduction
          1. End-Users By Value
        2. Hospitals
          1. By Value
        3. Homecare
          1. By Value
        4. Specialty Clinics
          1. By Value
        5. Others
          1. By Value
    8. Canada
    1. Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Papillary Thyroid Cancer
        1. By Value
      3. Follicular Thyroid Cancer
        1. By Value
      4. Hurthle Cell Cancer
        1. By Value
      5. Medullary Thyroid Cancer (MTC)
        1. By Value
      6. Anaplastic Thyroid Cancer
        1. By Value
    3. By Treatment
      1. Introduction
        1. Treatment By Value
      2. Medication
        1. By Value
      3. Chemotherapy
        1. By Value
      4. Radioactive Iodine (Radioiodine) Therapy
        1. By Value
      5. Hormone Therapy
        1. By Value
    4. By Drug Type
      1. Introduction
        1. Drug Type By Value
      2. Thyroid Desiccated
        1. By Value
      3. Sorafenib
        1. By Value
      4. Thyrotropin Alfa
        1. By Value
      5. Vandetanib
        1. By Value
      6. Doxorubicin
        1. By Value
      7. Cabozantinib
        1. By Value
      8. Lenvatini
        1. By Value
      9. Sodium Iodide I-131
        1. By Value
      10. Dabrafenib
        1. By Value
      11. Trametinib
        1. By Value
      12. Others
        1. By Value
    5. By Route of Administration
      1. Introduction
        1. Route of Administration By Value
      2. Oral
        1. By Value
      3. Injectable
        1. By Value
      4. Others
        1. By Value
    6. By End-Users
      1. Introduction
        1. End-Users By Value
      2. Hospitals
        1. By Value
      3. Homecare
        1. By Value
      4. Specialty Clinics
        1. By Value
      5. Others
        1. By Value
    7. U.K.
      1. By Type
        1. Introduction
          1. Type By Value
        2. Papillary Thyroid Cancer
          1. By Value
        3. Follicular Thyroid Cancer
          1. By Value
        4. Hurthle Cell Cancer
          1. By Value
        5. Medullary Thyroid Cancer (MTC)
          1. By Value
        6. Anaplastic Thyroid Cancer
          1. By Value
      2. By Treatment
        1. Introduction
          1. Treatment By Value
        2. Medication
          1. By Value
        3. Chemotherapy
          1. By Value
        4. Radioactive Iodine (Radioiodine) Therapy
          1. By Value
        5. Hormone Therapy
          1. By Value
      3. By Drug Type
        1. Introduction
          1. Drug Type By Value
        2. Thyroid Desiccated
          1. By Value
        3. Sorafenib
          1. By Value
        4. Thyrotropin Alfa
          1. By Value
        5. Vandetanib
          1. By Value
        6. Doxorubicin
          1. By Value
        7. Cabozantinib
          1. By Value
        8. Lenvatini
          1. By Value
        9. Sodium Iodide I-131
          1. By Value
        10. Dabrafenib
          1. By Value
        11. Trametinib
          1. By Value
        12. Others
          1. By Value
      4. By Route of Administration
        1. Introduction
          1. Route of Administration By Value
        2. Oral
          1. By Value
        3. Injectable
          1. By Value
        4. Others
          1. By Value
      5. By End-Users
        1. Introduction
          1. End-Users By Value
        2. Hospitals
          1. By Value
        3. Homecare
          1. By Value
        4. Specialty Clinics
          1. By Value
        5. Others
          1. By Value
    8. Germany
    9. France
    10. Spain
    11. Italy
    12. Russia
    13. Nordic
    14. Benelux
    15. Rest of Europe
    1. Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Papillary Thyroid Cancer
        1. By Value
      3. Follicular Thyroid Cancer
        1. By Value
      4. Hurthle Cell Cancer
        1. By Value
      5. Medullary Thyroid Cancer (MTC)
        1. By Value
      6. Anaplastic Thyroid Cancer
        1. By Value
    3. By Treatment
      1. Introduction
        1. Treatment By Value
      2. Medication
        1. By Value
      3. Chemotherapy
        1. By Value
      4. Radioactive Iodine (Radioiodine) Therapy
        1. By Value
      5. Hormone Therapy
        1. By Value
    4. By Drug Type
      1. Introduction
        1. Drug Type By Value
      2. Thyroid Desiccated
        1. By Value
      3. Sorafenib
        1. By Value
      4. Thyrotropin Alfa
        1. By Value
      5. Vandetanib
        1. By Value
      6. Doxorubicin
        1. By Value
      7. Cabozantinib
        1. By Value
      8. Lenvatini
        1. By Value
      9. Sodium Iodide I-131
        1. By Value
      10. Dabrafenib
        1. By Value
      11. Trametinib
        1. By Value
      12. Others
        1. By Value
    5. By Route of Administration
      1. Introduction
        1. Route of Administration By Value
      2. Oral
        1. By Value
      3. Injectable
        1. By Value
      4. Others
        1. By Value
    6. By End-Users
      1. Introduction
        1. End-Users By Value
      2. Hospitals
        1. By Value
      3. Homecare
        1. By Value
      4. Specialty Clinics
        1. By Value
      5. Others
        1. By Value
    7. China
      1. By Type
        1. Introduction
          1. Type By Value
        2. Papillary Thyroid Cancer
          1. By Value
        3. Follicular Thyroid Cancer
          1. By Value
        4. Hurthle Cell Cancer
          1. By Value
        5. Medullary Thyroid Cancer (MTC)
          1. By Value
        6. Anaplastic Thyroid Cancer
          1. By Value
      2. By Treatment
        1. Introduction
          1. Treatment By Value
        2. Medication
          1. By Value
        3. Chemotherapy
          1. By Value
        4. Radioactive Iodine (Radioiodine) Therapy
          1. By Value
        5. Hormone Therapy
          1. By Value
      3. By Drug Type
        1. Introduction
          1. Drug Type By Value
        2. Thyroid Desiccated
          1. By Value
        3. Sorafenib
          1. By Value
        4. Thyrotropin Alfa
          1. By Value
        5. Vandetanib
          1. By Value
        6. Doxorubicin
          1. By Value
        7. Cabozantinib
          1. By Value
        8. Lenvatini
          1. By Value
        9. Sodium Iodide I-131
          1. By Value
        10. Dabrafenib
          1. By Value
        11. Trametinib
          1. By Value
        12. Others
          1. By Value
      4. By Route of Administration
        1. Introduction
          1. Route of Administration By Value
        2. Oral
          1. By Value
        3. Injectable
          1. By Value
        4. Others
          1. By Value
      5. By End-Users
        1. Introduction
          1. End-Users By Value
        2. Hospitals
          1. By Value
        3. Homecare
          1. By Value
        4. Specialty Clinics
          1. By Value
        5. Others
          1. By Value
    8. Korea
    9. Japan
    10. India
    11. Australia
    12. Singapore
    13. Taiwan
    14. South East Asia
    15. Rest of Asia-Pacific
    1. Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Papillary Thyroid Cancer
        1. By Value
      3. Follicular Thyroid Cancer
        1. By Value
      4. Hurthle Cell Cancer
        1. By Value
      5. Medullary Thyroid Cancer (MTC)
        1. By Value
      6. Anaplastic Thyroid Cancer
        1. By Value
    3. By Treatment
      1. Introduction
        1. Treatment By Value
      2. Medication
        1. By Value
      3. Chemotherapy
        1. By Value
      4. Radioactive Iodine (Radioiodine) Therapy
        1. By Value
      5. Hormone Therapy
        1. By Value
    4. By Drug Type
      1. Introduction
        1. Drug Type By Value
      2. Thyroid Desiccated
        1. By Value
      3. Sorafenib
        1. By Value
      4. Thyrotropin Alfa
        1. By Value
      5. Vandetanib
        1. By Value
      6. Doxorubicin
        1. By Value
      7. Cabozantinib
        1. By Value
      8. Lenvatini
        1. By Value
      9. Sodium Iodide I-131
        1. By Value
      10. Dabrafenib
        1. By Value
      11. Trametinib
        1. By Value
      12. Others
        1. By Value
    5. By Route of Administration
      1. Introduction
        1. Route of Administration By Value
      2. Oral
        1. By Value
      3. Injectable
        1. By Value
      4. Others
        1. By Value
    6. By End-Users
      1. Introduction
        1. End-Users By Value
      2. Hospitals
        1. By Value
      3. Homecare
        1. By Value
      4. Specialty Clinics
        1. By Value
      5. Others
        1. By Value
    7. UAE
      1. By Type
        1. Introduction
          1. Type By Value
        2. Papillary Thyroid Cancer
          1. By Value
        3. Follicular Thyroid Cancer
          1. By Value
        4. Hurthle Cell Cancer
          1. By Value
        5. Medullary Thyroid Cancer (MTC)
          1. By Value
        6. Anaplastic Thyroid Cancer
          1. By Value
      2. By Treatment
        1. Introduction
          1. Treatment By Value
        2. Medication
          1. By Value
        3. Chemotherapy
          1. By Value
        4. Radioactive Iodine (Radioiodine) Therapy
          1. By Value
        5. Hormone Therapy
          1. By Value
      3. By Drug Type
        1. Introduction
          1. Drug Type By Value
        2. Thyroid Desiccated
          1. By Value
        3. Sorafenib
          1. By Value
        4. Thyrotropin Alfa
          1. By Value
        5. Vandetanib
          1. By Value
        6. Doxorubicin
          1. By Value
        7. Cabozantinib
          1. By Value
        8. Lenvatini
          1. By Value
        9. Sodium Iodide I-131
          1. By Value
        10. Dabrafenib
          1. By Value
        11. Trametinib
          1. By Value
        12. Others
          1. By Value
      4. By Route of Administration
        1. Introduction
          1. Route of Administration By Value
        2. Oral
          1. By Value
        3. Injectable
          1. By Value
        4. Others
          1. By Value
      5. By End-Users
        1. Introduction
          1. End-Users By Value
        2. Hospitals
          1. By Value
        3. Homecare
          1. By Value
        4. Specialty Clinics
          1. By Value
        5. Others
          1. By Value
    8. Turkey
    9. Saudi Arabia
    10. South Africa
    11. Egypt
    12. Nigeria
    13. Rest of MEA
    1. Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Papillary Thyroid Cancer
        1. By Value
      3. Follicular Thyroid Cancer
        1. By Value
      4. Hurthle Cell Cancer
        1. By Value
      5. Medullary Thyroid Cancer (MTC)
        1. By Value
      6. Anaplastic Thyroid Cancer
        1. By Value
    3. By Treatment
      1. Introduction
        1. Treatment By Value
      2. Medication
        1. By Value
      3. Chemotherapy
        1. By Value
      4. Radioactive Iodine (Radioiodine) Therapy
        1. By Value
      5. Hormone Therapy
        1. By Value
    4. By Drug Type
      1. Introduction
        1. Drug Type By Value
      2. Thyroid Desiccated
        1. By Value
      3. Sorafenib
        1. By Value
      4. Thyrotropin Alfa
        1. By Value
      5. Vandetanib
        1. By Value
      6. Doxorubicin
        1. By Value
      7. Cabozantinib
        1. By Value
      8. Lenvatini
        1. By Value
      9. Sodium Iodide I-131
        1. By Value
      10. Dabrafenib
        1. By Value
      11. Trametinib
        1. By Value
      12. Others
        1. By Value
    5. By Route of Administration
      1. Introduction
        1. Route of Administration By Value
      2. Oral
        1. By Value
      3. Injectable
        1. By Value
      4. Others
        1. By Value
    6. By End-Users
      1. Introduction
        1. End-Users By Value
      2. Hospitals
        1. By Value
      3. Homecare
        1. By Value
      4. Specialty Clinics
        1. By Value
      5. Others
        1. By Value
    7. Brazil
      1. By Type
        1. Introduction
          1. Type By Value
        2. Papillary Thyroid Cancer
          1. By Value
        3. Follicular Thyroid Cancer
          1. By Value
        4. Hurthle Cell Cancer
          1. By Value
        5. Medullary Thyroid Cancer (MTC)
          1. By Value
        6. Anaplastic Thyroid Cancer
          1. By Value
      2. By Treatment
        1. Introduction
          1. Treatment By Value
        2. Medication
          1. By Value
        3. Chemotherapy
          1. By Value
        4. Radioactive Iodine (Radioiodine) Therapy
          1. By Value
        5. Hormone Therapy
          1. By Value
      3. By Drug Type
        1. Introduction
          1. Drug Type By Value
        2. Thyroid Desiccated
          1. By Value
        3. Sorafenib
          1. By Value
        4. Thyrotropin Alfa
          1. By Value
        5. Vandetanib
          1. By Value
        6. Doxorubicin
          1. By Value
        7. Cabozantinib
          1. By Value
        8. Lenvatini
          1. By Value
        9. Sodium Iodide I-131
          1. By Value
        10. Dabrafenib
          1. By Value
        11. Trametinib
          1. By Value
        12. Others
          1. By Value
      4. By Route of Administration
        1. Introduction
          1. Route of Administration By Value
        2. Oral
          1. By Value
        3. Injectable
          1. By Value
        4. Others
          1. By Value
      5. By End-Users
        1. Introduction
          1. End-Users By Value
        2. Hospitals
          1. By Value
        3. Homecare
          1. By Value
        4. Specialty Clinics
          1. By Value
        5. Others
          1. By Value
    8. Mexico
    9. Argentina
    10. Chile
    11. Colombia
    12. Rest of LATAM
    1. Thyroid Cancer Drugs Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    1. Mylan N.V. 
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. Bristol-Myers Squibb Company 
    3. Teva Pharmaceutical Industries Ltd 
    4. Jerome Stevens Pharmaceuticals Inc 
    5. Baxter 
    6. Abbott 
    7. Celgene Corporation 
    8. AstraZeneca 
    9. GlaxoSmithKline plc 
    10. Eisai Co. Ltd 
    11. Takeda Pharmaceutical Company Ltd
    12. Biovista
    13. Cytori Therapeutics Inc
    14. Bayer AG 
    15. Novartis AG 
    16. Bio-Path Holdings Inc. 
    17. Vascular Biogenics 
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  3. Disclaimer

Related Reports

Global Report
Breast Cancer Drugs Market Size The global breast cancer drugs market size was valued at USD 34.25 billion in 2024 and is projected to reach from USD 37.30 billion in 2025 to USD 80.34 billion by 2033, growing at a CAGR of 8.90% durin
Buy Now
Global Report
The global renal cancer drug market size was valued at USD 5.7 Billion in 2022 and is projected to reach USD 9.31 Billion by 2031, registering a CAGR of 5.6% during the forecast period (2023-2031). The primary variables impac
Buy Now

Purchase Benefits

  • Eligible for a free updated report next year
  • Completely customizable scope
  • 30% discount on your next purchase
  • Dedicated account manager
  • Query resolution within 24 hours
  • Permission to print the report

We are featured on :

www.straitsresearch.com
© Copyright 2025. All rights Reserved.